多柔比星联合拓扑替康治疗卵巢癌疗效  

Effect of doxorubicin combined with topotecan for treating patients with ovarian cancer

作　　者：张永香 孟萍 段广庭 ZHANG Yongxiang;MENG Ping;DUAN Gangting(Qinghai Transportation Hospital, Qinghai Province, 810001)

机构地区：[1]青海省交通医院,西宁810001

出　　处：《中国计划生育学杂志》2021年第2期300-303,共4页Chinese Journal of Family Planning

摘　　要：目的:探究多柔比星联合拓扑替康治疗卵巢癌效果。方法:选取2019年02月—2020年1月本院收治的卵巢癌患者128例分为对照组和观察组各64例。对照组给予多柔比星治疗,观察组给予多柔比星联合拓扑替康治疗。比较两组治疗前后卵巢功能、疗效、不良反应及血清学指标情况。结果:治疗后观察组血清血管内皮生长因子(233.0±154.0 ng/L)、碱性成纤维生长因子(70.8±16.2 ng/L)、肿瘤抗原CA125(283.7±198.3 U/L)、黄体生成素(283.7±198.3 U/L)和卵泡刺激素(20.6±1.2 U/L)水平均低于对照组,肿瘤坏死因子(67.5±16.8 ng/L)和雌二醇(261.3±11.2 pmol/L)水平高于对照组,临床总有效(92.2%)高于对照组(70.3%),不良反应总发生(6.3%)低于对照组(23.4%)(均P<0.05)。结论:多柔比星联合拓扑替康治疗卵巢癌临床疗效显著,可保护患者卵巢功能且不良反应少,安全性高。Objective:To explore the Effect of doxorubicin combined with topotecan for treating patients with ovarian cancer.Methods:128 patients with ovarian cancer were selected and were divided into two groups(64 cases in each group)from February 2019 to January 2020.The patients in the control group were treated with doxorubicin,while the patients in the study group were treated with doxorubicin combined with topotecan.The ovarian function,therapeutic effect,adverse reactions,and serological indicator of the patients were compared between the two groups.Results:After treatment,the serum vascular endothelial growth factor(VEGF)level,basic fibroblast growth factor(BFGF)level,tumor antigen CAL25 level,luteinizing hormone(LH)level,and follicle-stimulating hormone(FSH)level of the patients in the observation group were 233.0±154.0ng/L,70.8±16.2ng/L,283.7±198.3U/L,and 20.6±1.2 U/L,respectively,which were significant lower than those of the patients in the control group,but the levels of tumor necrosis factor and estradiol of the patients in the observation group were 67.5±16.8 ng/L and 261.3±11.2 pmol/L,which were significant higher than those of the patients in the control group.The total clinical efficacy(92.2%)of the patients in the observation group was significant higher than that(70.3%)of the patients in the control group,but the total incidence of adverse reaction(6.3%)of the patients in the observation group was significant lower than that(23.4%)of the patients in the control group(all P<0.05).Conclusion:Doxorubicin combined with topotecan for treating the patients with ovarian cancer has significant effectiveness,it can protect their ovarian function with less adverse reaction and with high safety.

关 键 词：卵巢癌 多柔比星 拓扑替康 血清因子 性激素 不良反应 临床效果 

分 类 号：R737.31[医药卫生—肿瘤]